newsfilter
← Latest News
Business Wire·

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

GMI-1687, a highly potent E-selectin antagonist, is being developed as a potential point-of-care treatment for inflammatory diseases with initial focus on sickle cell disease (SCD) Single ascending dose study is